The amount of ERCOT‘s large load interconnection requests ballooned to more than 230 gigawatts this year, a massive increase from the 63 gigawatts reported in December 2024. The agency, which operates ...

Planned data center construction shows no signs of fading, with new additions to require 2.7x — nearly triple — the sector’s current demand for electricity over the next decade, according to a new ...

Andrew Wang, M.D., Cardiologist and Professor of Medicine, Duke University School of Medicine presented a pre-specified responder analysis from MAPLE-HCM evaluating five clinically relevant measures ...

The amount of capital pouring into AI data center projects is staggering. Last week, Microsoft, Alphabet, Meta, and Amazon reported their 2025 capital expenditures would total roughly $370 billion, ...

The study showed no link between load-managed players and a decreased risk of injury. Shaun Powell The NBA sent data from an exhaustive study to its teams this week that showed no link between ...

Most people with HCM can participate in mild- to moderate-intensity exercise safely. When it comes to vigorous exercise and competitive sports, there may be a need for additional guidance from your ...

Arrhythmias, or irregular heart rhythms, are common complications of HCM. The thickened heart muscle disrupts the electrical pathways that coordinate heartbeat, leading to arrhythmias. Atrial ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

Oracle Corp. today announced a series of new agentic artificial intelligence extensions to its Fusion Cloud Human Capital Management suite, bringing the number of agents in the application to more ...

Workday Rising 2025 opens with announcements of new AI agents for HCM and finance, but the big news is the new Workday Build developer platform and Data Cloud, along with consumption-based pricing.

MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is ...